Real Money authors - Bruce Kamich

Bruce Kamich

Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs. 

In addition to writing for Kamich has been teaching technical analysis at Baruch College for the past twenty years.

Kamich was one of the earliest Chartered Market Technicians  or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works"  and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (
Email Bruce Kamich

Recent Articles By The Author

CarMax Could Run Into Some Engine Trouble in the Weeks Ahead

Here's how I would play the stock right now.

The Charts of Symantec Are More Bullish Than Bearish

Let's review the charts and indicators to see how they look after the company's 'on and off company acquisition news'.

United Rentals Looks Like They Made a Top Reversal and Will Head Lower

Let's check the charts to see if we should invest or just rent.

Clorox Stock Looks Ready for a Clean Upside Breakout: Buy Strength

Here's how to play the shares.

Dine Brands Could Decline in the Weeks Ahead - Avoid the Long Side for Now

Let's check on the charts and indicators to see what traders and investors think.

Marvell Technology Is Breaking Out on the Upside: How to Play It

Checking out the latest charts and indicators.

CSX Looks Like It Will Eventually Break the 200-Day Average Line - Play Defense

Let's check out the charts and indicators.

Domino's Pizza Could Get Even Colder

DPZ stock looks particularly vulnerable to further weakness now.

Starbucks Looks Extended on the Upside - Lock in Some Gains

Let's look closer at the price action over the past 12 months.

Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet

With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight